Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volasertib - Boehringer Ingelheim/Oncoheroes Biosciences

X
Drug Profile

Volasertib - Boehringer Ingelheim/Oncoheroes Biosciences

Alternative Names: BI-6727

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Oncoheroes Biosciences
  • Class Amides; Antineoplastics; Piperazines; Pteridines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Rhabdomyosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
  • No development reported Chronic myelomonocytic leukaemia; Rhabdomyosarcoma; Solid tumours; Urogenital cancer

Most Recent Events

  • 03 Jun 2024 Notable Labs has patent protection for volasertib in USA, European Patent Office, Germany, France, United Kingdom, and Japan before June 2024
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Rhabdomyosarcoma in Unknown (IV, Infusion)
  • 05 Mar 2024 Notable Labs plans a phase II trial for Acute myeloid leukemia (Second-line therapy or greater) in the second quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top